Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. After experiencing losses in the second quarter, small-cap stocks notably increased in the third quarter. The Russell 2000 Growth Index (up 8.41%) underperformed the Russell 2000 Value Index (up 10.11%). In addition, please check the fund’s top five holdings to know its best picks in 2024.
Carillon Eagle Small Cap Growth Fund highlighted stocks like Lantheus Holdings, Inc. (NASDAQ:LNTH), in the third quarter 2024 investor letter. Lantheus Holdings, Inc. (NASDAQ:LNTH) is a company that manufactures diagnostic and therapeutic products used by healthcare providers to diagnose and treat heart, cancer, and other medical conditions. The one-month return of Lantheus Holdings, Inc. (NASDAQ:LNTH) was -18.68%, and its shares gained 29.77% of their value over the last 52 weeks. On November 26, 2024, Lantheus Holdings, Inc. (NASDAQ:LNTH) stock closed at $89.53 per share with a market capitalization of $6.225 billion.
Carillon Eagle Small Cap Growth Fund stated the following regarding Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q3 2024 investor letter:
“Lantheus Holdings, Inc. (NASDAQ:LNTH) is a fully integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence (AI) solutions used to fight serious medical conditions. The company had a strong quarter that exceeded revenue expectations, highlighted by the Centers for Medicare and Medicaid Services’ (CMS) proposed update to reimbursement policies, ensuring separate outpatient reimbursement for Lantheus’s flagship product, PYLARIFY, a prostate cancer diagnostic imaging agent. This came just in time as the company’s traditional pass-through payment status was about to expire, alleviating potential revenue pressure. Additionally, Lantheus has a promising pipeline of diagnostic radiopharmaceuticals to support future growth.”
A medical professional performing a pulmonary function assessment on a patient.
Lantheus Holdings, Inc. (NASDAQ:LNTH) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held Lantheus Holdings, Inc. (NASDAQ:LNTH) at the end of the third quarter which was 34 in the previous quarter. Lantheus Holdings, Inc.’s (NASDAQ: LNTH) consolidated net revenue for the third quarter was approximately $378.7 million, representing an 18.4% increase year-over-year. While we acknowledge the potential of Lantheus Holdings, Inc. (NASDAQ:LNTH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we discussed Lantheus Holdings, Inc. (NASDAQ:LNTH) and shared the list of most promising medical stocks according to hedge funds. In addition, please check out our hedge fund investor letters Q3 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.